Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | TYMS | P04818 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8501316 | 0.79 | TDP2 (0.58) | TDP2TGM2CES1CASP3CCNB2 | |
| SCHEMBL26638890 | 0.79 | TDP2 (0.58) | TDP2TGM2CES1APPMAOA | |
| SCHEMBL16750516 | 0.75 | MEN1 (0.40) | TDP2 | |
| SCHEMBL14453945 | 0.73 | ALDH1A1 (0.33) | CES1GSK3B | |
| SCHEMBL1963896 | 0.72 | S100A4 (0.50) | TDP2TGM2CES1CASP3MAOA | |
| SCHEMBL16267346 | 0.72 | MAOA (0.50) | TDP2TGM2CES1CASP3MAOA | |
| SCHEMBL21224167 | 0.72 | TGM2 (0.50) | TDP2TGM2CES1CASP3MAOA | |
| SCHEMBL1795929 | 0.72 | TGM2 (0.50) | TDP2TGM2CES1CASP3MAOA | |
| SCHEMBL5823309 | 0.71 | S100A4 (0.56) | TDP2TGM2CES1CDK5LRRK2 | |
| SCHEMBL3254156 | 0.71 | MAOB (0.52) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20220102650-A1 | PHOTOELECTRIC CONVERSION ELEMENT, DEVICE, AND POWER SUPPLY MODULE | RICOH COMPANY, LTD. (JP) | 2022-03-31 | — | — | US | disclosed |
| US-20210135128-A1 | PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, OPTICAL SENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | TDP2 656/4885TGM2 4425/4885CES1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.